Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
https://link.springer.com/content/pdf/10.1007/s10147-022-02163-3.pdf
Reference52 articles.
1. WHO Solidarity Trial Consortium (2021) Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 384:497–511
2. Nakai H, Matsumura N (2022) The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol, paper in press
3. Li H, Liu ZY, Wu N et al (2020) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19:107
4. Murai J, Huang SN, Das BB et al (2012) Trapping of PARP1 and PARP2 by Clinical PARP inhibitors. Cancer Res 72:5588–5599
5. Hopkins TA, Shi Y, Rodriguez LE et al (2015) Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 13:1465–1477
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Niraparib as maintenance therapy in Japan: a retrospective observational study using a Japanese claims database;Journal of Gynecologic Oncology;2025
2. Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study;British Journal of Cancer;2024-08-30
3. Artificial Intelligence-Based Histopathological Subtyping of High-Grade Serous Ovarian Cancer;The American Journal of Pathology;2024-07
4. Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients;International Journal of Gynecologic Cancer;2024-06-10
5. Identification of ovarian high-grade endometrioid-type tumors through multi-omics analysis: JGOG3025-TR2 study;2024-04-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3